{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:14:30Z","timestamp":1789470870349,"version":"build-2803163510"},"reference-count":14,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,24]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Inhibitor development in patients with nonsevere hemophilia A is associated with predicted novel binding of HLA-DRB1 with FVIII peptides. Inhibitor development associated with high-risk F8 mutations is due, in part, to high levels of novel HLA-DRB1 FVIII peptide binding.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018019323","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T11:55:16Z","timestamp":1532346916000},"page":"1750-1755","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["HLA-DRB1\u2013factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study"],"prefix":"10.1182","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2391-2016","authenticated-orcid":false,"given":"Christine L.","family":"Kempton","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University of School of Medicine, Atlanta, GA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1027-7639","authenticated-orcid":false,"given":"Amanda B.","family":"Payne","sequence":"additional","affiliation":[{"name":"Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,7,23]]},"reference":[{"issue":"11","key":"2019111617164109800_B1","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111617164109800_B2","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","article-title":"Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A","volume":"122","author":"Eckhardt","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111617164109800_B3","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/j.1538-7836.2010.04013.x","article-title":"In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study","volume":"8","author":"Kempton","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2019111617164109800_B4","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ajh.23269","article-title":"Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A","volume":"87","author":"Kempton","year":"2012","journal-title":"Am J Hematol"},{"issue":"7","key":"2019111617164109800_B5","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/jth.13711","article-title":"Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study","volume":"15","author":"van Velzen","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2019111617164109800_B6","first-page":"10","article-title":"The association between genetic variants involved in immune response and inhibitors among persons with hemophilia A: a systematic review and meta-analysis","volume":"1","author":"Payne","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2019111617164109800_B7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bjh.13131","article-title":"A large-scale computational study of inhibitor risk in non-severe haemophilia A","volume":"168","author":"Shepherd","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111617164109800_B8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1538-7836.2006.01840.x","article-title":"Int22h-related inversions causing hemophilia A: a novel insight into their origin and a new more discriminant PCR test for their detection","volume":"4","author":"Bagnall","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111617164109800_B9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2516.2011.02700.x","article-title":"F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race\/ethnicity","volume":"18","author":"Miller","year":"2012","journal-title":"Haemophilia"},{"issue":"4","key":"2019111617164109800_B10","doi-asserted-by":"crossref","first-page":"e1000048","DOI":"10.1371\/journal.pcbi.1000048","article-title":"A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach","volume":"4","author":"Wang","year":"2008","journal-title":"PLOS Comput Biol"},{"issue":"1","key":"2019111617164109800_B11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1186\/1471-2105-11-568","article-title":"Peptide binding predictions for HLA DR, DP and DQ molecules","volume":"11","author":"Wang","year":"2010","journal-title":"BMC Bioinformatics"},{"issue":"6","key":"2019111617164109800_B12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/9858","article-title":"Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices","volume":"17","author":"Sturniolo","year":"1999","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2019111617164109800_B13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri1805","article-title":"MHC class II proteins and disease: a structural perspective","volume":"6","author":"Jones","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2019111617164109800_B14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/hae.12276","article-title":"In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene","volume":"20","author":"Pashov","year":"2014","journal-title":"Haemophilia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/14\/1750\/881119\/advances019323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/14\/1750\/881119\/advances019323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T17:16:58Z","timestamp":1573924618000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/14\/1750\/16240\/HLADRB1factor-VIII-binding-is-a-risk-factor-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,23]]},"references-count":14,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018,7,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018019323","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,23]]}}}